Expertise in
9
conditions

Magalie Joris

Amiens, FR 
Expertise in
9
conditions
Amiens, FR 

Overview

Magalie Joris practices practicing medicine in Amiens, France.

Ms. Joris is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses B-Cell Lymphoma, Acute Myelomonocytic Leukemia, Non-Hodgkin Lymphoma, Leukemia, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 6 clinical trials.

Gender

Female

Locations

Amiens, France
Other Locations
CHU Estaing
Clermont-ferrand, France
Lyon, 69410, France
Bordeaux, France
CHU de Rennes
Rennes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy With Relapsed or Refractory Acute Myeloid Leukemia or HR-MDS .
Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy With Relapsed or Refractory Acute Myeloid Leukemia or HR-MDS .
Enrollment Status: Completed
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: BST-236
Study Phase: Phase 2
A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML in Relapse After Allohematopoietic Stem Cell Transplantation
A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML in Relapse After Allohematopoietic Stem Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2026
Intervention Type: Drug
Study Drugs: Venetoclax, Azacitidine
Study Phase: Phase 1/Phase 2
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Ibrutinib
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
CPX-351 in Higher Risk Myelodysplastic Syndromes: a Phase I/ II Study as First Line or After Hypomethylating-agents Failure
CPX-351 in Higher Risk Myelodysplastic Syndromes: a Phase I/ II Study as First Line or After Hypomethylating-agents Failure
Enrollment Status: Completed
Publish Date: July 07, 2022
Intervention Type: Drug
Study Drug: CPX-351
Study Phase: Phase 1/Phase 2
Treatment of Steroid Refractory Gastro-intestinal Acute Graft-versus-Host disEase afteR AllogeneiC Hematopoietic Stem celL Transplantation With fEcal Microbiota tranSfer
Treatment of Steroid Refractory Gastro-intestinal Acute Graft-versus-Host disEase afteR AllogeneiC Hematopoietic Stem celL Transplantation With fEcal Microbiota tranSfer
Enrollment Status: Completed
Publish Date: February 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

51 Total Publications

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.
Journal: Journal of hematology & oncology
Published: April 01, 2026

Frequently Asked Questions about Magalie Joris

Is Magalie Joris a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Magalie Joris is classified as an Distinguished expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Magalie Joris participate in research or clinical trials?

Yes. Magalie Joris has published 51 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Magalie Joris's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Joris's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile